Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark X Sliwkowski

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Clinical Breast Cancer|July 7, 2011
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancerHoward A Burris, Jay Tibbitts, Scott N Holden, et al.
Nature Reviews. Clinical Oncology|November 30, 2011
Treatment of HER2-positive breast cancer: current status and future perspectivesCarlos L Arteaga, Mark X Sliwkowski, C Kent Osborne, et al.
Cancer Immunology Research|November 13, 2014
Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCCScot D Liu, Cecile Chalouni, Judy C Young, et al.
Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.
Cancer Cell|April 20, 2004
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexMatthew C Franklin, Kendall D Carey, Felix F Vajdos, et al.
Nature Communications|September 8, 2016
High cell-surface density of HER2 deforms cell membranesInhee Chung, Mike Reichelt, Lily Shao, et al.
Cancer Research|November 23, 2012
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiationShyhmin Huang, Chunrong Li, Eric A Armstrong, et al.
Cancer Research|July 18, 2008
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapySi Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, et al.
Cancer Cell|May 5, 2009
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Teemu T Junttila, Robert W Akita, Kathryn Parsons, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 29, 2010
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in miceNelson L Jumbe, Yan Xin, Douglas D Leipold, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Clinical Breast Cancer|July 7, 2011
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancerHoward A Burris, Jay Tibbitts, Scott N Holden, et al.
Nature Reviews. Clinical Oncology|November 30, 2011
Treatment of HER2-positive breast cancer: current status and future perspectivesCarlos L Arteaga, Mark X Sliwkowski, C Kent Osborne, et al.
Cancer Immunology Research|November 13, 2014
Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCCScot D Liu, Cecile Chalouni, Judy C Young, et al.
Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.
Cancer Cell|April 20, 2004
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexMatthew C Franklin, Kendall D Carey, Felix F Vajdos, et al.
Nature Communications|September 8, 2016
High cell-surface density of HER2 deforms cell membranesInhee Chung, Mike Reichelt, Lily Shao, et al.
Cancer Research|November 23, 2012
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiationShyhmin Huang, Chunrong Li, Eric A Armstrong, et al.
Cancer Research|July 18, 2008
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapySi Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, et al.
Cancer Cell|May 5, 2009
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941Teemu T Junttila, Robert W Akita, Kathryn Parsons, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 29, 2010
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in miceNelson L Jumbe, Yan Xin, Douglas D Leipold, et al.
Pageof 5